Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Other Non-Current Liabilities (2016 - 2025)

Guided Therapeutics' Other Non-Current Liabilities history spans 12 years, with the latest figure at $37000.0 for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 68.64% to $37000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $37000.0, a 68.64% decrease, with the full-year FY2025 number at $37000.0, down 68.64% from a year prior.
  • Other Non-Current Liabilities hit $37000.0 in Q4 2025 for Guided Therapeutics, down from $79000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for GTHP hit a ceiling of $118000.0 in Q4 2024 and a floor of -$38000.0 in Q3 2021.
  • Historically, Other Non-Current Liabilities has averaged $29416.7 across 4 years, with a median of $26000.0 in 2021.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 115.62% in 2022 and later skyrocketed 361.54% in 2025.
  • Tracing GTHP's Other Non-Current Liabilities over 4 years: stood at $32000.0 in 2021, then plummeted by 115.62% to -$5000.0 in 2022, then surged by 2460.0% to $118000.0 in 2024, then tumbled by 68.64% to $37000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for GTHP at $37000.0 in Q4 2025, $79000.0 in Q3 2025, and $60000.0 in Q2 2025.